ONC
The table below shows BeOne Medicines AG's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $201.34M | $44.08M | -$308.57M | -$563.78M | -$236.56M | $125.09M |
| Capital expenditure | $40.79M | $56.41M | $156.58M | $125.58M | $45.13M | $42.39M |
| Investing cash flow | -$45.51M | -$121.94M | -$209.83M | $241.06M | $210.39M | $291.95M |
| Dividends paid | - | - | - | - |
BeOne Medicines AG reported operating cash flow of $1.13B for fiscal year 2025. That is up 901.8% from -$140.63M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$89.51M (FY 2016) to $1.13B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $68.63M | -$33.78M | $162.29M | -$19.87M | -$11.27M | $107.42M |